Advertisement

A Review of Retinoblastoma from the Perspective of Integrative Medicine

  • Bin Li
  • Xiao Zhang
Chapter
Part of the Advances in Visual Science and Eye Diseases book series (AVSED, volume 3)

Abstract

Retinoblastoma (RB) is a common primary intraocular malignant tumor in children. The retinoblastoma gene (RB gene) is the first tumor-suppressor gene found in humans. It has been confirmed that there are abnormalities of the RB pathway in all human tumor cells. Throughout the history of retinoblastoma research, material changes have happened in the pathogenesis and treatment concept of RB for more than half a century, which include the following: (1) It was previously considered that the formation of retinoblastoma is due to the absence of function of RB1 tumor-suppressor gene. Related research published by “Lancet Oncology” in 2013 has shown that the activation of MYCN proto-oncogene can also lead to its occurrence. (2) It was considered that the eyeball removal and external radiation therapy are the two cornerstones of RB therapy in traditional treatment. However, in recent years, the individualized comprehensive treatment of chemical volume reduction combined with local therapy has gradually become the first-line treatment.

References

  1. 1.
    Abramson DH. Retinoblastoma in the 20th century: past success and future challenges the Weisenfeld lecture. Invest Ophthalmol Vis Sci. 2005;46(8):2683–91.CrossRefPubMedGoogle Scholar
  2. 2.
    Qian J. Some problems should be paid attention to in the treatment of retinoblastoma. Ophthalmology. 2009;18(6):367–9.Google Scholar
  3. 3.
    Li Y, Fen G, Yi Y. Research status and prospect of retinoblastoma in China. Chin J Ophthalmol. 2004;40(4):217–9.Google Scholar
  4. 4.
    Bai S, Ren R, Shi J, et al. Retinoblastoma in the Beijing Tongren Hospital from 1957 to 2006: clinicopathological findings. Br J Ophthalmol. 2011;95(8):1072–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Chantada GL, Dunkel IJ, de Dávila MT, et al. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004;88(8):1069–73.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Suryawanshi P, Ramadwar M, Dikshit R, et al. A study of pathologic risk factors in postchemoreduced, enucleated specimens of advanced retinoblastomas in a developing country. Arch Pathol Lab Med. 2011;135:1017–23.CrossRefPubMedGoogle Scholar
  7. 7.
    Kaliki S, Shields CL, Rojanaporn D, et al. High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology. 2013;120(5):997–1003.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and People's Medical Publishing House, PR of China 2020

Authors and Affiliations

  • Bin Li
    • 1
  • Xiao Zhang
    • 2
  1. 1.Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing Institute of Ophthalmology, Beijing Tongren HospitalCapital Medical UniversityBeijingChina
  2. 2.Department of OphthalmologyPeking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations